{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T19:03:20Z","timestamp":1775070200304,"version":"3.50.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To estimate the cost-effectiveness of the levonorgestrel intrauterine device (IUD) as an endometrial cancer prevention strategy in obese women.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>A modified Markov model was used to compare IUD placement at age 50 with usual care among women with a body mass index (BMI, kg\/m<jats:sup>2<\/jats:sup>) 40 or greater or BMI 30 or greater. The effects of obesity on incidence and survival were incorporated. The IUD was assumed to confer a 50% reduction in cancer incidence over 5 years. Costs of IUD and cancer care were included. Clinical outcomes were cancer diagnosis and deaths from cancer. Incremental cost-effectiveness ratios were calculated in 2015 U.S. dollars per year of life saved. One-way and two-way sensitivity analyses and Monte Carlo probabilistic analyses were performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>For a 50 year old with BMI 40 or greater, the IUD strategy is costlier and more effective than usual care with an incremental cost-effectiveness ratio of $74,707 per year of life saved. If the protective effect of the levonorgestrel IUD is assumed to be 10 years, the incremental cost-effectiveness ratio decreases to $37,858 per year of life saved. In sensitivity analysis, a levonorgestrel IUD that reduces cancer incidence by at least 68% in women with BMIs of 40 or greater or costs less than $500 is potentially cost-effective. For BMI 30 or greater, the incremental cost-effectiveness ratio of IUD strategy is $137,223 per year of life saved compared with usual care. In Monte Carlo analysis, IUD placement for BMI 40 or greater is cost-effective in 50% of simulations at a willingness-to-pay threshold of $100,000 per year of life saved.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>The levonorgestrel IUD is a potentially cost-effective strategy for prevention of deaths from endometrial cancer in obese women.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000001616","type":"journal-article","created":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T12:52:10Z","timestamp":1473252730000},"page":"747-753","source":"Crossref","is-referenced-by-count":16,"title":["Levonorgestrel Intrauterine Device as an Endometrial Cancer Prevention Strategy in Obese Women"],"prefix":"10.1097","volume":"128","author":[{"given":"Joseph A.","family":"Dottino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vic","family":"Hasselblad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeles Alvarez","family":"Secord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan R.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junzo","family":"Chino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura J.","family":"Havrilesky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230711","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1136\/bmj.39367.495995.AE","article-title":"Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study","volume":"335","author":"Reeves","year":"2007","journal-title":"BMJ"},{"key":"R2-20230711","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/jcp.2010.085951","article-title":"The pathogenesis of endometrial carcinomas at menopause: facts and figures","volume":"64","author":"Sivridis","year":"2011","journal-title":"J Clin Pathol"},{"key":"R3-20230711","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10552-006-0113-8","article-title":"Anthropometric factors and risk of endometrial cancer: the European prospective investigation into cancer and nutrition","volume":"18","author":"Friedenreich","year":"2007","journal-title":"Cancer Causes Control"},{"key":"R4-20230711","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.puhe.2015.04.017","article-title":"The effect of body mass index on endometrial cancer: a meta-analysis","volume":"129","author":"Jenabi","year":"2015","journal-title":"Public Health"},{"key":"R5-20230711","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/jnci\/djh291","article-title":"Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands Cohort Study","volume":"96","author":"Schouten","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"R6-20230711","doi-asserted-by":"crossref","first-page":"579.e1","DOI":"10.1016\/j.ajog.2013.08.007","article-title":"The risk of uterine malignancy is linearly associated with body mass index in a cohort of US women","volume":"209","author":"Ward","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"R7-20230711","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ygyno.2015.10.020","article-title":"Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis","volume":"140","author":"Secord","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R8-20230711","first-page":"215","article-title":"Catch it before it kills: progesterone, obesity, and the prevention of endometrial cancer","volume":"14","author":"Carlson","year":"2012","journal-title":"Discov Med"},{"key":"R9-20230711","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/1471-0528.12499","article-title":"Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial","volume":"121","author":"Orbo","year":"2014","journal-title":"BJOG"},{"key":"R10-20230711","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1097\/AOG.0b013e31826bb121","article-title":"Management of endometrial precancers","volume":"120","author":"Trimble","year":"2012","journal-title":"Obstet Gynecol"},{"key":"R11-20230711","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10549-013-2496-z","article-title":"Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA\/PAI-1 in node negative primary breast cancer","volume":"138","author":"Jacobs","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"R12-20230711","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","article-title":"Markov models in medical decision making: a practical guide","volume":"13","author":"Sonnenberg","year":"1993","journal-title":"Med Decis Making"},{"key":"R13-20230711","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"R14-20230711","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/AOG.0000000000000356","article-title":"Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland","volume":"124","author":"Soini","year":"2014","journal-title":"Obstet Gynecol"},{"key":"R15-20230711","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/AOG.0000000000000144","article-title":"Effects of age, parity, and device type on complications and discontinuation of intrauterine devices","volume":"123","author":"Aoun","year":"2014","journal-title":"Obstet Gynecol"},{"key":"R16-20230711","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.contraception.2015.01.007","article-title":"Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices","volume":"91","author":"Heinemann","year":"2015","journal-title":"Contraception"},{"key":"R17-20230711","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1097\/AOG.0b013e318273364c","article-title":"Neisseria gonorrhea and Chlamydia trachomatis screening at intrauterine device insertion and pelvic inflammatory disease","volume":"120","author":"Sufrin","year":"2012","journal-title":"Obstet Gynecol"},{"key":"R18-20230711","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1002\/cncr.22351","article-title":"Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinoma: a Gynecologic Oncology Group study","volume":"107","author":"von Gruenigen","year":"2006","journal-title":"Cancer"},{"key":"R19-20230711","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2006.10.045","article-title":"Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study","volume":"105","author":"Modesitt","year":"2007","journal-title":"Gynecol Oncol"},{"key":"R20-20230711","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1287\/opre.37.2.210","article-title":"The confidence profile method: a Bayesian method for assessing health technologies","volume":"37","author":"Eddy","year":"1989","journal-title":"Oper Res"},{"key":"R21-20230711","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1001\/jama.2014.732","article-title":"Prevalence of childhood and adult obesity in the United States, 2011-2012","volume":"311","author":"Ogden","year":"2014","journal-title":"JAMA"},{"key":"R22-20230711","first-page":"1","article-title":"United States life tables, 2010","volume":"63","author":"Arias","year":"2014","journal-title":"Natl Vital Stat Rep"},{"key":"R23-20230711","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/jnci\/djn103","article-title":"Cost of care for elderly cancer patients in the United States","volume":"100","author":"Yabroff","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R24-20230711","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.fertnstert.2014.09.032","article-title":"Timing of postpartum intrauterine device placement: a cost-effectiveness analysis","volume":"103","author":"Washington","year":"2015","journal-title":"Fertil Steril"},{"key":"R25-20230711","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ygyno.2009.03.039","article-title":"Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship","volume":"114","author":"Fader","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R26-20230711","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ygyno.2011.11.043","article-title":"Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature","volume":"125","author":"Baker","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"suppl l","key":"R27-20230711","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/j.contraception.2007.01.015","article-title":"Endometrial effects of intrauterine levonorgestrel","volume":"75","author":"Guttinger","year":"2007","journal-title":"Contraception"},{"key":"R28-20230711","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/AOG.0b013e3182994c43","article-title":"Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis","volume":"122","author":"Peragallo Urrutia","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R29-20230711","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/01.AOG.0000178754.88912.b9","article-title":"Use of the levonorgestrel-releasing intrauterine system and breast cancer","volume":"106","author":"Backman","year":"2005","journal-title":"Obstet Gynecol"},{"key":"R30-20230711","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1097\/gme.0b013e31821606c5","article-title":"Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis","volume":"18","author":"Somboonporn","year":"2011","journal-title":"Menopause"},{"key":"R31-20230711","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1158\/1055-9965.EPI-13-0298","article-title":"Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review","volume":"22","author":"Gierisch","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R32-20230711","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ygyno.2012.01.003","article-title":"Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review","volume":"125","author":"Gunderson","year":"2012","journal-title":"Gynecol Oncol"},{"key":"R33-20230711","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/AOG.0b013e31817d53a4","article-title":"Cost-effectiveness analysis of endometrial cancer prevention strategies for obese women","volume":"112","author":"Kwon","year":"2008","journal-title":"Obstet Gynecol"},{"key":"R34-20230711","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.contraception.2015.04.006","article-title":"Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system","volume":"92","author":"Eisenberg","year":"2015","journal-title":"Contraception"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006250-201610000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T19:52:38Z","timestamp":1689105158000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006250-201610000-00010"}},"subtitle":["A Cost-Effectiveness Analysis"],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000001616","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}